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Abstract 
The prognostic significance of Hypoxia-inducible factor-1α (HIF-1α) in patients with bone and soft tissue sarcoma 
remains controversial. To investigate the impact of its expression on survival outcomes, we performed a meta-analysis. 
Comprehensive literature searches were conducted in PubMed, Web of Science, Embase and Cochrane Library. A 
total of 16 studies published from 2006 to 2015 were included. We found that expression of HIF-1α was significantly 
associated with higher rate of metastasis (RR 3.21, 95 % CI 2.12–4.84, P < 0.001), poorer overall survival (HR 2.05, 95 % 
CI 1.51–2.77, P < 0.001) and poorer disease-free survival (HR 2.05, 95 % CI 1.55–2.70, P < 0.001). In addition, when 
subgroup analysis was conducted according to histology type, the significant correlations to poor overall survival and 
disease-free survival were also observed in patients with osteosarcoma, chondrosarcoma and soft tissue sarcoma. 
Publication bias was not found and sensitivity analysis showed the results were stable. In conclusion, HIF-1α expres-
sion might be an effective predicative factor of poor prognosis for bone and soft tissue sarcoma.
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Background
Sarcomas are a heterogeneous group of mesenchymal 
malignant tumors that can be divided into two general 
categories: primary bone sarcoma and soft tissue sarcoma 
(Skubitz and D’Adamo 2007). Primary bone sarcomas 
mainly include osteosarcoma, Ewing’s sarcoma, chon-
drosarcoma; soft tissue sarcomas mainly include synovial 
sarcoma, leiomyosarcoma, liposarcoma and angiosar-
coma. With the emergence of effective chemotherapy 
regimens and the development of surgical techniques, 
the survival rate of sarcoma patients increased (Hwang 
et al. 2014). However, metastasis still occurs in 20–55 % 
of these patients, and it remains the main cause of death 
(Nakamura et al. 2009; Tsukushi et al. 2014). Efforts in the 
last 20 years including the changes of the chemotherapy 
drugs, the doses and the administration schemes did 
not significantly improve prognosis (Luetke et  al. 2014). 
Advanced treatment methods are urgently needed. There 
is no doubt that effective prognostic factors are important 
for researchers and clinicians to select reasonable treat-
ment methods for sarcoma patients (Wang et al. 2015).
Hypoxia-inducible factor-1 (HIF-1) plays a central role in 
cellular response to hypoxia, which is a heterodimer com-
posing of an oxygen-liable α subunit and a constitutively 
expressed β subunit. In normoxic environment, HIF-1α is 
rapidly ubiquitinated and degradated by von Hippel–Lin-
dau tumor-suppressor protein (Epstein et  al. 2001; Jaak-
kola et al. 2001). In contrast, under hypoxia environment, 
the degradation process is suppressed and HIF-1α trans-
locates from the cell plasma to the nucleus, where it could 
regulate the expression of more than 60 genes involved in 
crucial aspects of tumor biology (Semenza 2001; Kimura 
et  al. 2001). Through this way, tumor cells could activate 
adaptive responses to match metabolic demands with 
oxygen supply, and survive under intratumoral hypoxia 
microenvironments. Overall, HIF-α expression could 
contribute to tumor progression in the way of sustaining 
energy metabolism, maintaining biosynthesis and promot-
ing tumor cell invasion and migration.
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It has been confirmed by a number of studies that 
expression of HIF-1α is correlated with poor prognosis 
in various cancers, including gastric, esophageal and lung 
cancers (Zhang et al. 2013; Ping et al. 2014; Wang et al. 
2014). However, the prognostic role of HIF-1α expres-
sion in bone and soft tissue sarcoma has not reached a 
consensus since inconsistent results were reported in 
previous studies (Zhao et  al. 2015; Kim et  al. 2015; Hu 
et  al. 2015; Guo et  al. 2014; Smeland et  al. 2012; Chen 
et al. 2012a, b, 2011; Zeng et al. 2010; Huang et al. 2010; 
Boeuf et al. 2010; Hoffmann et al. 2009; Mizobuchi et al. 
2008; Kubo et al. 2008; Chen et al. 2008; Yang et al. 2007; 
Shintani et al. 2006). To date, there has been no compre-
hensive meta-analysis to clarify its prognostic role in sar-
coma. Therefore, we conducted the current meta-analysis 
to combine published studies and to comprehensively 
assess the prognostic significance of HIF-1α expression 
in bone and soft tissue sarcoma.
Methods
We conducted comprehensive electronic literature 
searches in PubMed, Web of Science, Embase and 
Cochrane Library with no restriction to language and 
date of publication. The last search was conducted on July 
17, 2015. The search terms were as follows: (“HIF-1” OR 
“Hypoxia Inducible Factor-1”) AND (“sarcoma” OR “soft 
tissue sarcoma” OR “bone sarcoma” OR “osteosarcoma” 
OR “chondrosarcoma” OR “Ewing sarcoma” OR “leio-
myosarcoma” OR “angiosarcoma” OR “histiocytoma” OR 
“liposarcoma” OR “rhabdomyosarcoma” OR “synovio-
sarcoma”). In addition, reference list of identified articles 
were traced by Google Scholar for potential studies.
Studies were eligible for inclusion if they met the fol-
lowing criteria: (1) included patients with pathologically 
confirmed bone and soft tissue sarcoma; (2) investigated 
the association between HIF-1α expression and the out-
comes of sarcoma patients; (3) provided information on 
metastasis, disease-free survival or overall survival; (4) 
were in language of English or Chinese. The following 
studies were excluded: (1) reported overlapping patients; 
(2) non-human research; (3) reviews, letters and arti-
cles from conferences; (4) with insufficient information. 
When articles recruiting overlapping patients were iden-
tified, the most recent published article was included in 
the meta-analysis. The literatures were evaluated inde-
pendently by two authors (YJ Li and WB Zhang) for eli-
gibility. Any disagreement was discussed and adjudicated 
by corresponding author (CQ Tu).
Data extraction and quality assessment
Data of interest was extracted independently by two 
authors (YJ Li and SJ Li). The required data included: 
(1) basic information of each publication including first 
author, year of publication, study period, follow-up dura-
tion and study design; (2) data of patient and tumor 
including patient source, number, age, percentage of 
positive HIF-1α expression and histology type of tumor; 
(3) outcome measures including overall survival, disease-
free survival, Kaplan–Meier curves and metastasis; and 
(4) other variables including the methods of quantitative 
HIF-1α measurements and definition of positivity (the 
cut-off value).
Each included article’s quality was evaluated using 
Newcastle–Ottawa Scale (NOS) (www.ohri.ca/programs/
clinical_epidemiology/oxford.asp). Based on the quality 
of each study in selection, comparability and exposure, 
a score up to 9 points was appointed. Articles with 6 or 
more of the NOS scores were deemed as high-quality and 
were included in the meta-analysis.
Statistical analysis
To assess the prognostic significance of HIF-1α expres-
sion, we calculated the pooled hazard ratio (HR) or rela-
tive risk (RR) with its corresponding 95  % confidence 
interval (CI). If the HRs or RRs were given explicitly in 
the publications, we used the original data. If the data 
were not given explicitly, we calculated the HRs or RRs 
with 95 % CIs from outcome data available in the articles 
or from Kaplan–Meier curves through methods reported 
by Tierney et al. (2007), Xu et al. (2013), Zhuang and Wei 
(2014) and Kubo et al. (2015).
Heterogeneity was evaluated using Chi squared test 
and I2 statistic. If P > 0.1 and I2 < 50 %, the heterogeneity 
was not considered as significant. Otherwise, the hetero-
geneity was not significant. Both fixed-model and ran-
dom effect model were conducted to calculate the overall 
estimate. Publication bias was evaluated by Egger’s test 
and Begg’s test. If P > 0.05 and the funnel plot was visu-
ally symmetry, it was not considered as significant. In 
addition, sensitivity analysis was conducted to evaluate 
the stability of the results by omitting individual study 
sequentially. All statistical analyses were conducted using 
STATA version 12.0 (Stata Corp., College Station, TX).
Results
Searches results and study characteristics
A total of 437 articles were identified in the initial 
searches after duplicated removed. After initial screening 
and full-text viewing, 420 articles were removed because 
they do not meet our inclusion criteria. Particularly, we 
identified two articles recruiting overlapping patients in 
the full-text viewing process. After discussion, the ear-
lier published article was excluded (Chen et al. 2012a, b). 
One study in Chinese language was also excluded, for its 
unfamiliarity for non-Chinese speakers. Eventually, 16 
articles published from 2006 to 2015 were included in the 
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current meta-analysis (Fig. 1) (Zhao et al. 2015; Kim et al. 
2015; Hu et al. 2015; Guo et al. 2014; Smeland et al. 2012; 
Chen et al. 2008, 2012a, b, 2011; Zeng et al. 2010; Huang 
et al. 2010; Boeuf et al. 2010; Hoffmann et al. 2009; Miz-
obuchi et  al. 2008; Kubo et  al. 2008; Yang et  al. 2007; 
Shintani et  al. 2006). The NOS scores of the included 
studies are counted and shown in Table 1. All the studies 
have 6 or more of the NOS scores.
Baseline characteristics of the included 16 studies are 
tabulated and shown in Table 1. Briefly, all the 16 litera-
tures were in English. Two studies were prospectively 
designed and 14 studies were retrospectively designed. 
Study sample sizes ranged from 20 to 200, and a total of 
942 sarcoma patients were included. The rate of HIF-1α 
expression ranged from 33.8 to 79.9 % and 531 patients 
had positive HIF-1α expression.
Quantitative data synthesis
A total of 10 studies with 685 patients were included in 
the analysis of overall survival. The heterogeneity was not 
significant (I2 = 15.4 %, P = 0.302). Expression of HIF-1α 
was significantly associated with poor overall survival 
under fixed-effect model (HR 2.05, 95  % CI 1.51–2.77, 
P  <  0.001) and random effect model (HR 2.10, 95  % CI 
1.50–2.95, P < 0.001) (Fig. 2).
In the analysis of disease-free survival, 8 studies with 
359 patients were included. The heterogeneity was not 
significant (I2 = 0.0 %, P = 0.768). The analysis indicated 
that expression of HIF-1α was significantly associated 
with poor disease-free survival under fixed effect model 
(HR 2.05, 95  % CI 1.55–2.70, P  <  0.001) and random-
effect model (HR 2.05, 95  % CI 1.55–2.70, P  <  0.001) 
(Fig. 3).
For metastasis, 6 studies with 363 patients were 
included. The heterogeneity was not significant 
(I2 = 0.0 %, P = 0.632). The analysis showed that HIF-1α 
expression was significantly associated with higher rate 
of metastasis under fixed effect model (RR 3.21, 95 % CI 
2.13–4.84, P < 0.001) and random effect model (RR 2.79, 
95 % CI 1.89–4.12, P < 0.001) (Fig. 4).
Subgroup analysis of osteosarcoma
The pooled HR estimate for overall survival in osteosar-
coma group was 2.32 (95  % CI 1.47–3.66) under both 
fixed-effect model and random-effect model. For disease-
free survival, the pooled HR estimate was 2.43 (95 % CI 
1.16–5.09) under both fixed-effect model and random-
effect model. The heterogeneity was not significant 
(Table 2).
Subgroup analysis of soft tissue sarcoma
Under fixed-effect model, significantly poorer overall 
survival (HR 1.68, 95 % CI 1.07–2.63, P = 0.025) and dis-
ease-free survival (HR 2.06, 95 % CI 1.41–3.02, P < 0.001) 
were found in soft tissue sarcoma patients with expres-
sion of HIF-1α.However, under random effect model, the 
correlation to overall survival was not found to be signifi-
cant (HR 1.94, 95 % CI 0.98–3.83, P = 0.055), while the 
correlation to poorer disease-free survival was still signif-
icant (HR 2.06, 95 % CI 1.41–3.02, P < 0.001).The hetero-
geneity was not found to be significant (Table 2).
Subgroup analysis of chondrosarcoma
Significantly poorer overall survival (fixed-effect model: 
HR 2.83, 95  % CI 1.11–7.22; Random-effect model: HR 
2.83, 95 % CI 1.11–7.22) and disease-free survival (fixed-
effect model: HR 1.87, 95 % CI 1.15–3.04; Random-effect 
model: HR 1.96, 95 % CI 1.06–3.64) for HIF-1α expres-
sion were observed in chondrosarcoma patients without 
significant heterogeneity (Table 2).
Sensitivity analysis
By omitting one single study at a time, the effect of the 
study on the overall estimate could be investigated. The 
omitting of any study in the analyses of overall survival, 
disease-free survival and metastasis made no significant 
changes in the overall results, indicating that the analyses 
were statistically stable and reliable (Fig. 5).
Evaluation of publication bias
Egger’s test did not found any publication bias among 
the studies (P =  0.108, 0.062 and 0.083 for the analysis 
of overall survival, disease-free survival and metastasis, 
respectively). Visual evaluation of the Begg’s funnel plots 
found no apparent asymmetry (Fig. 6).
Literature search results:
PubMed (n=152)







Articles included in the
meta-analysis (n=16)
Articles excluded for:
3. Reported overlapping patients (n=1)
Articles excluded according to
inclusion creteria (n=409)
1. Reviews and letters (n=3)
4. Included patients with other tumors (n=2)
5. In the language of Chinese (n=1)
Fig. 1 Flow diagram of study selection
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Discussion
Bone and soft tissue sarcoma is the third leading cause of 
cancer related death in children and young adults (Siegel 
et al. 2015; Damron et al. 2007). With the emergence of 
effective chemotherapy regimens and the development 
of surgical techniques, the survival rate raised. However, 
metastasis is common and long-time survival of these 





































1 1.50 2.10 2.95
Heterogeneity: I−squared = 15.4%, p = 0.302
2.05 (1.51, 2.77) 100.00

































Heterogeneity: I−squared = 0.0%, p = 0.768
2.05 (1.55, 2.70) 100.00
2.051.55 2.70
Fig. 3 Meta-analysis of the effect of HIF-1α expression on disease-free survival
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et al. 2014). Identification of effective prognostic factors 
is important to get a better understanding of the patho-
genesis of bone and soft tissue sarcoma, and to develop 
new effective treatment methods. To date, several bio-
markers have been discovered as prognostic factors of 
bone and soft tissue sarcoma, which play an important 
role in helping researchers and clinicians to choose ideal 
treatment methods (Zhuang and Wei 2014; Li and Geng 
2010).
HIF-1α is an important regulator in cellular response 
to hypoxia in both malignant and normal tissues. Under 
hypoxia microenvironments, HIF-1α becomes stable and 
translocates from the cell plasma to the nucleus, where it 
dimerizes with HIF-1β and binds to the hypoxia response 
elements (HREs). Through the way, HIF-1α could regu-
late target genes which are associated with crucial aspects 
of tumor biology including angiogenesis, energy metabo-



























 Heterogeneity: I−squared = 0.0%, p = 0.632
Fig. 4 Meta-analysis of the effect of HIF-1α expression on metastasis
Table 2 Main results of meta-analysis
OS overall survival, DFS disease-free survival, MET metastasis, HR hazard ratio, RR relative risk
No. of studies Patients Heterogeneity test (I2, P) Combined estimate (95 % CI)/P value
Fixed-effect model Random-effect model
Overall patients
 OS 10 685 15.4 %, 0.302 HR 2.05 (1.51–2.77)/<0.001 HR 2.10 (1.50–2.95)/<0.001
 DFS 8 359 0.0 %, 0.768 HR 2.05 (1.55–2.70)/<0.001 HR 2.05 (1.55–2.70)/<0.001
 MET 6 363 0.0 %, 0.632 RR 3.21 (2.13–4.84)/<0.001 RR 2.79 (1.89–4.12)/<0.001
Osteosarcoma
 OS 4 270 0.0 %, 0.692 HR 2.32 (1.47–3.66)/<0.001 HR 2.32 (1.47–3.66)/<0.001
 DFS 3 138 0.0 %, 0.473 HR 2.43 (1.16–5.09)/0.018 HR 2.43 (1.16–5.09)/0.018
Soft tissue sarcoma
 OS 5 381 47.8 %, 0.105 HR 1.68 (1.07–2.63)/0.025 HR 1.94 (0.98–3.83)/0.055
 DFS 3 136 0.0 %, 0.657 HR 2.06 (1.41–3.02)/<0.001 HR 2.06 (1.41–3.02)/<0.001
Chondrosarcoma
 OS 1 34 – HR 2.83 (1.11–7.22)/0.030 HR 2.83 (1.11–7.22)/0.030
 DFS 2 85 29.7 %, 0.233 HR 1.87 (1.15–3.04)/0.011 HR 1.96 (1.06–3.64)/0.033
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1.431.51   2.05   2.77   3.37
 Zhao H 2015
 Kim 2015
 Guo M 2014
 Smeland 2012
 Chen C 2011
 Zeng 2010
 Huang J 2010
 Yang Q 2007
 Shintani 2006
 Lower CI Limit  Estimate  Upper CI Limit
 Meta−analysis estimates, given named study is omitted
  1.46   2.05  1.55   2.70   3.06
 Kim 2015
 Hu T 2015
 Chen Y 2012
 Huang J 2010
 Boeuf 2010
 Kubo 2008
 Yang Q 2007
 Shintani 2006
 Lower CI Limit  Estimate  Upper CI Limit
 Meta−analysis estimates, given named study is omitted
  1.82   3.21  2.13   4.84   5.81
 Zhao H 2015
 Guo M 2014
 Chen Y 2012
 Zeng 2010
 Mizobuchi 2008
 Chen W 2008
 Lower CI Limit  Estimate  Upper CI Limit




Fig. 5 Sensitivity analysis of the effect of HIF-1α expression on a overall survival, b disease-free survival and c metastasis
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cell adaptive to the intratumoral hypoxia (Semenza 2001; 
Tsai and Wu 2012). Overall, the expression of HIF-1α 
contributes to the progression of many solid tumors 
through the way of sustaining energy metabolism, main-
taining biosynthesis and promoting tumor cell invasion 
and migration (Stoeltzing et  al. 2004). The prognostic 
significance of HIF-1α in tumors has been widely studied 
and literatures have identified that HIF-1α expression is 
an indicator for poor survival in several cancers (Zhang 
et  al. 2013; Ping et  al. 2014; Wang et  al. 2014). How-
ever, its prognostic role in bone and soft tissue sarcoma 
has not been well established and reached a consensus. 
Therefore, we performed the meta-analysis to derive an 
overall pooled estimation of the association between 
HIF-1α expression and outcomes of sarcoma patients.
In the current meta-analysis, we combined 16 stud-
ies with 942 sarcoma patients comparing the outcomes 
of metastasis and survival according to the level of 
HIF-1α expression. We found that expression of HIF-1α 
was significantly associated with poor overall survival, 
poor disease-free survival and higher rate of metasta-
sis. In addition, when subgroup analysis was conducted 
according to histology type, the significant correlations 
to poor overall survival and disease-free survival were 
also observed in patients with osteosarcoma, chondro-
sarcoma and soft tissue sarcoma. The sensitivity analysis 
showed that the results were statistically stable and reli-
able. Therefore, HIF-1α may be an effective prognostic 
factor of poor prognosis for bone and soft tissue sar-
coma. To our knowledge, it is the first time to systemati-
cally evaluate the prognostic role of HIF-1α expression in 
bone and soft tissue sarcoma.
As the hazard ratio was chose to assess the prog-
nostic significance, it is important to also mention the 
changes in the time-to-event measurement. In majority 
of the included studies, the disease-free and overall sur-
vival rate of patients with positive expression of HIF-1α 
was lower than those with negative expression from the 
beginning of follow-up. The gap between the two groups 
would be enlarged as the follow-up duration went on. In 
particular, only one of the included studies did not show 
this time-to-event pattern (Smeland et al. 2012), in which 
the survival curves of the two groups were continuous 
intersected, with a slightly trend of favorable survival for 
the negative expression group.
The heterogeneity was not found to be significant in 
the analyses, however, it should be noted that our meta-
analysis could not totally excluded biases, which could be 
arisen from several aspects. Firstly, the methods of quan-
titative HIF-1α measurement differed among these stud-
ies. Although the most common method was IHC, the 
studies did not use the same antibody, and its dilutions 
were also different. Because the type and the concentra-
tion of the antibody could affect the sensitivity of IHC, 
the differences may lead to a potential bias. In addition, 
differences also existed in the cut-off value to determine 
the positive expression of HIF-1α. To date, there have 
been no uniform criteria for the methodology and deter-






































Fig. 6 Begg’s funnel plot for publication bias of the correlation 
between HIF-1α expression and a overall survival, b disease-free 
survival and c metastasis
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these methodological variances could bring heterogene-
ity and lower the reliability of pooled results. However, 
because of the small groups of studies using the same 
antibody and cut-off value, we could not perform a sub-
group analysis to clarify this technical problem, and uni-
form criteria are urgently needed for future studies to 
draw a more homogeneous conclusion.
To ensure the accuracy of the pooled results and mini-
mize its bias derived from the heterogeneity among the 
included studies, we calculated the HRs or RRs with both 
fixed and random effect models adopted. In majority 
of the analyses, the pooled results under fixed and ran-
dom effect models were consistent (Table 2). Only in the 
analysis of overall survival in patients with soft tissue sar-
coma, the result under random effect model was negative 
(P = 0.055), which was inconsistent with the result under 
fixed effect model (P = 0.025). Nevertheless, an obvious 
tendency could be observed in the negative result (HR 
1.94, 95  % CI 0.98–3.83). Thus, it is reasonable to con-
sider that the pooled results of the current meta-analysis 
were relatively accurate and the bias was limited.
It is also worthy to mention the method to extrapo-
late HRs or RRs from the included articles. When these 
data from multivariate survival analysis were reported, 
we used them directly. If the HRs or RRs were not given 
explicitly, we calculated them from outcome data avail-
able in the articles. If this was impracticable, we extrap-
olated them from Kaplan–Meier curves by univariate 
analysis (Xu et al. 2013; Zhuang and Wei 2014; Kubo et al. 
2015). The estimation might be less reliable than the HRs 
given directly in the papers. Therefore, the results of the 
current meta-analysis should be interpreted with caution 
and should be confirmed by more well-designed prospec-
tive studies with appropriate multivariate analyses.
Publication bias is another major concern in all forms 
of meta-analyses, since positive results trend to be pub-
lished in journals. To minimize publication bias, we 
attempted to perform literature searches as complete as 
possible, using Web of Science, PubMed, Embase and 
Cochrane Library. The publication bias was not found 
in our analyses, however, it should be noted that we only 
included articles in English or Chinese. Secondly, we 
excluded conference abstracts since it did not contain 
sufficient information for aggregation. Besides, the Begg’s 
test has relative low power to detect the publication bias 
if the number of included studies were not large (Sterne 
et al. 2000), and P values of the Egger’s test are nearing 
0.05 (Fig. 6). Thus, these restrictions may bring potential 
source of publication bias to the current meta-analysis.
In conclusion, this meta-analysis demonstrates that 
HIF-1α expression may be an effective predicative fac-
tor of poor prognosis for bone and soft tissue sarcoma. 
Further well-designed prospective studies are needed to 
validate our findings.
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